



## **Cohere Medical Policy – Diaphragmatic/Phrenic Nerve Electrical Stimulators**

*Clinical Guidelines for Medical Necessity Review*

**Version:** 1  
**Revision Date:** March 13, 2025

# Important Notices

## Notices & Disclaimers:

**GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.**

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

© 2025 Cohere Health, Inc. All Rights Reserved.

## Other Notices:

HCPCS® and CPT® copyright 2025 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

## Guideline Information:

**Specialty Area:** Sleep Medicine

**Guideline Name:** Cohere Medical Policy - Diaphragmatic/Phrenic Nerve Electrical Stimulators

**Date of last literature review:** 03/12/2025

**Document last updated:** 03/12/2025

**Type:** ☒ Adult (18+ yo) | ☐ Pediatric (0-17 yo)

## Table of Contents

<b>Important Notices</b>	<b>2</b>
<b>Medical Necessity Criteria</b>	<b>4</b>
<b>Service: Diaphragmatic/Phrenic Nerve Electrical Stimulators</b>	<b>4</b>
Recommended Clinical Approach	4
Medical Necessity Criteria	4
Indications	4
Non-Indications	4
Level of Care Criteria	4
Procedure Codes (CPT/HCPCS)	4
<b>Medical Evidence</b>	<b>5</b>
<b>References</b>	<b>6</b>
<b>Clinical Guideline Revision History/Information</b>	<b>7</b>

# Medical Necessity Criteria

## ***Service: Diaphragmatic/Phrenic Nerve Electrical Stimulators***

### **Recommended Clinical Approach**

The phrenic nerve controls the movement of the diaphragm to facilitate respiration by allowing air to move into the lungs. Electrical stimulation of the phrenic nerve may be achieved by the implantation of a device that can detect cessation of breathing and trigger contraction of the diaphragm to simulate natural respiration. These devices have been used for short-term daily respite from mechanical ventilation in patients with high-level (C3 and higher) spinal cord injuries (SCI) as well as conditions affecting respiration such as central alveolar hypoventilation syndrome.<sup>1-2</sup> Clinical studies are ongoing related to proposed use in central sleep apnea (CSA), amyotrophic lateral sclerosis (ALS), and difficult-to-wean mechanically ventilated individuals.<sup>3-6</sup>

### **Medical Necessity Criteria**

#### **Indications**

→ **Diaphragmatic/phrenic nerve electrical stimulation** is considered appropriate if **ALL** of the following are **TRUE**:

- ◆ The patient is 18 years of age or older<sup>7</sup>; **AND**
- ◆ There is sufficient diaphragmatic function to accommodate electrical stimulation<sup>7</sup>; **AND**
- ◆ There is intact phrenic nerve function<sup>7</sup>; **AND**
- ◆ Normal chest anatomy is present for adequate implantation; **AND**
- ◆ The patient and/or caregiver is able to safely use the device; **AND**
- ◆ **ANY** of the following:
  - **ALL** of the following:
    - Noninvasive or invasive ventilator-dependent, stable high cervical spinal cord injury (SCI)(C3 vertebral level or higher)<sup>1,7-9</sup>; **AND**
    - The patient is unable to breathe independently for at least 4 continuous hours per day without the assistance of a mechanical ventilator<sup>1,7</sup>; **OR**
  - Noninvasive or invasive ventilator-dependent patients with central alveolar hypoventilation syndrome<sup>2,10</sup>; **OR**

- Replacement, adjustment, repair, or removal of a diaphragmatic/phrenic nerve electrical stimulation device when medically necessary.

**NOTE:** The diaphragmatic/phrenic nerve electrical stimulation device will be used according to FDA-approved indications.<sup>7</sup>

### Non-Indications

→ **Diaphragmatic/phrenic nerve electrical stimulation** is not considered appropriate if **ANY** of the following is **TRUE**:

- ◆ Central sleep apnea (e.g., remedē)<sup>3,11-13</sup>; **OR**
- ◆ Amyotrophic lateral sclerosis (ALS)<sup>4,14</sup>; **OR**
- ◆ Temporary respiratory insufficiency or difficult-to-wean patients on mechanical ventilation<sup>5,15</sup>; **OR**
- ◆ Denervation of the diaphragm.

### Level of Care Criteria

Outpatient

### Procedure Codes (CPT/HCPCS)

CPT/HCPCS Code	Code Description
33276	Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed
33277	Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)
33278	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)
33279	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only

33280	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only
33281	Repositioning of phrenic nerve stimulator transvenous lead(s)
33287	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator
33288	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)
93150	Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming
93151	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session
93152	Interrogation and programming of implanted phrenic nerve stimulator system during polysomnography
93153	Interrogation without programming of implanted phrenic nerve stimulator system

## Medical Evidence

Romero et al. (2012) completed a retrospective cohort study of cervical spinal cord injury (SCI) patients on permanent respiratory support. Potential for improved health-related quality of life (HRQL), long-term tolerability, and improved patient survival were indicators of effectiveness of the device. Of the 126 study participants, 38 patients received phrenic nerve stimulation (pacing) and 88 were mechanically ventilated. Patients included were those with high cervical SCI requiring volumetric mechanical ventilatory support from the moment of injury and exclusion criteria included active pulmonary infections, cancer, or other terminal illness. Mental disability and lack of family or caregiver support were not considered exclusions from the study. It was concluded that phrenic nerve stimulation, particularly in those younger members of the implant group, can impact long-term survival in patients with ventilator-dependent high SCI, with improved HRQL.<sup>9</sup>

Ataya and colleagues (2020) conducted the US-based RESCUE 1, multicenter, prospective open-label single treatment group feasibility study of adult patients for phrenic nerve stimulator implantation. These were mechanical ventilation-dependent patients who had failed at least two weaning trials and who received temporary transvenous diaphragmatic neurostimulation (TTDN) in conjunction with the standard of care. Patients in this study were adults 18 years of age or older and medically stable, having been on mechanical ventilation for at least 7 days. Hypovolemia, neuromuscular disorder, known or suspected phrenic nerve paralysis, terminal illness, or body mass index greater than or equal to 40 were among the study exclusion criteria. The study number was small with 14 patients, 11 who remained throughout the study and 7 who received the TTDN treatment. Two patients were unable to have the device placed due to inability to thread the guidewire due to potential anatomical barriers. The overall conclusion was that TTDN is safe and feasible in patients who are difficult to wean from mechanical ventilation. Future studies with greater numbers of participants are recommended.<sup>15</sup>

The RESCUE II study results were presented by Dres et al. (2021) in the American Journal of Respiratory Critical Care Medicine (American Thoracic

Society). The randomized, controlled, multi-center, open-label study focused upon patients 18 years of age or older on mechanical ventilation for greater than or equal to 4 days, having failed at least 2 weaning attempts. There were 127 eligible participants, with 112 randomized to 57 in the treatment group with temporary transvenous diaphragm neurostimulation (TTDN) and 55 in the control group. It was concluded that TTDN combined with standard management did not increase the proportion of successful weaning from mechanical ventilation when compared to solely standard treatment. Further studies were recommended.<sup>5</sup>

The American Academy of Sleep Medicine (AASM) maintains a 2012 guideline (Aurora et al.) for treatment of central sleep apnea with practice parameters. The literature review and meta-analyses do not reference diaphragmatic/phrenic nerve stimulation for central sleep apnea treatment and no recommendations located on this society's website currently support the use of the device.<sup>13</sup>

Sagalow et al. (2022) conducted a systematic review published in the American Journal of Cardiology regarding transvenous phrenic nerve stimulation of central sleep apnea. There were 232 patients in the studies examined who were implanted with the device. While the device was found overall to be of benefit to patients, there were multiple limitations, including that the device is only active at night when patients are lying supine. CSA is present both at nighttime and in the daytime in heart failure patients in the form of Cheyne–Stokes respirations. This is indicative of a more serious prognosis. Patients with significant heart failure are unable to lie in a supine position due to orthopnea. A meta-analysis was unable to be completed due to a lack of consistent outcome measures in the articles. The authors recommend additional studies in the future focusing on long-term outcomes and complications which would be independent from the initial clinical trial results.<sup>3</sup>

A 2019 publication in The American Journal of Respiratory and Critical Care Medicine (Guimarães-Costa et al.) reviews findings of two clinical trials: DiPALS (Diaphragm Pacing in Patients with Amyotrophic Lateral Sclerosis) and RespiStimALS (Early Diaphragm Pacing in Patients with Amyotrophic Lateral Sclerosis). A diaphragm biopsy substudy of the RespiStimALS protocol was



conducted on 39 patients, with 19 of these patients having left diaphragm electrical activity recording. Two of the 19 patients were eventually excluded with a resulting 17 patients (active stimulation in 8 patients and sham in 9) with electrophysiological recordings for analysis. Through this mechanistic evaluation, it was concluded that electrical stimulation delays reinnervation of denervated muscle fibers in the diaphragm with resulting harmful effect.<sup>14</sup>

## References

1. National Institute for Health and Care Excellence (NICE). Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury. Published August 21, 2024. <https://www.nice.org.uk/guidance/ipg792/resources/phrenic-nerve-pacing-for-ventilatordependent-high-cervical-spinal-cord-injury-pdf-1899876579329221>.
2. National Institute for Health and Care Excellence (NICE). Phrenic nerve pacing for congenital central hypoventilation syndrome. Published August 21, 2024. <https://www.nice.org.uk/guidance/ipg790/resources/phrenic-nerve-pacing-for-congenital-central-hypoventilation-syndrome-pdf-1899876575969989>.
3. Sagalow ES, Ananth A, Alapati R, Fares E, Fast Z. Transvenous phrenic nerve stimulation for central sleep apnea. *Am J Cardiol*. 2022;180:155–162.
4. DiPALS Writing Committee; DiPALS Study Group Collaborators. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. *Lancet Neurol* 2015; 14: 883–92.
5. Dres M, de Abreu MG, Merdji H, et al. Randomized clinical study of temporary transvenous phrenic nerve stimulation in difficult-to-wean patients. *Am J Respir Crit Care Med*. 2022 May 15;205(10):1169–1178. doi: 10.1164/rccm.202107-1709OC. PMID: 35108175; PMCID: PMC9872796.
6. Redline S. Sleep disordered breathing and cardiac disease. In: Libby P, Bonow RO, Mann DL, et al, Eds. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 12th Ed. 89; 1678–1686.
7. US Food and Drug Administration (FDA). Summary of safety and effectiveness data (SSED): NeuRx Diaphragm Pacing System (NeuRx DPS). Published March 31, 2023. <https://www.fda.gov>.
8. Garara B, Wood A, Marcus HJ, et al. Intramuscular diaphragmatic stimulation for patients with traumatic high cervical injuries and ventilator dependent respiratory failure: A systematic review of safety and effectiveness. *Injury*. 2016 Mar;47(3):539–44.

9. Romero FJ, Gambarrutta C, Garcia-Forcada A, et. al.: Long-term evaluation of phrenic nerve pacing for respiratory failure due to high cervical spinal cord injury. *Spinal Cord*. 2012; 50: pp. 895-898.
10. Nicholson KJ, Nosanov LB, Bowen KA, et al. Thoracoscopic placement of phrenic nerve pacers for diaphragm pacing in congenital central hypoventilation syndrome. *J Pediatr Surg*. 2015 Jan;50(1):78-81.
11. Fox H, Oldenburg O, Javaheri S, et al. Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. *Sleep*. 2019;42(11):zs158.
12. Luni FK, Daniels J, Link MS, et al. Meta-analysis of usefulness of phrenic nerve stimulation in central sleep apnea. *Am J Cardiol*. 2020;125(11): 1738-1744.
13. American Academy of Sleep Medicine (AASM). The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. Published August 2011. Updated May 2016. <https://aasmnet.org>.
14. Guimarães-Costa R, Nierat MC, Rivals I, et al. Implanted phrenic stimulation impairs local diaphragm myofiber reinnervation in amyotrophic lateral sclerosis. *American Journal of Respiratory and Critical Care Medicine*. 2019, 200 (9), pp.1183-1187. [ff10.1164/rccm.201903-0653LEff](https://doi.org/10.1164/rccm.201903-0653LEff). Ffhal-02860031f.
15. Ataya A, Silverman EP, Bagchi A, et al. Temporary transvenous diaphragmatic neurostimulation in prolonged mechanically ventilated patients: a feasibility trial (RESCUE 1). *Crit Care Explor*. 2020 Apr 29;2(4):e0106. doi: 10.1097/CCE.000000000000106. PMID: 32426748; PMCID: PMC7188416.

# Clinical Guideline Revision History/Information

Original Date: March 13, 2025		
Review History		